ࡱ> DFC bjbj! ! 00CfCf' a" 8LD,-t(:2"2"2"Z-\-\-\-\-\-\-$O03-P# 2"P#P#-l-8'8'8'P#Z-8'P#Z-8'8':(*tf*JuJ$v* F--0-*.3$H3**&3*L2"L~"68'","p2"2"2"--&02"2"2"-P#P#P#P#32"2"2"2"2"2"2"2"2" : ANTISERA REQUEST FORM Completed forms should be saved as a PDF and submitted to Comparative Medicine at  HYPERLINK "mailto:CompMed@research.usf.edu" CompMed@research.usf.edu for uploading into the ARC system for IACUC consideration. HYPERLINK  1. REQUESTING FACULTY MEMBER.  Requesting Faculty Members Name Department Campus Mailbox Phone 2. ALTERNATIVES, LITERATURE SEARCH, PRINCIPLES & PROCEDURES. Indicate by checking, that: A search for alternatives was conducted on ___________________ (date) of PubMed covering the years 20___ - 20___ ( > last 10 years) using the search terms animal, rabbit, research, pain, antiserum, antibody production, alternatives, antigen, inflammation, adjuvant, immunogen, early endpoint, anesthesia, analgesia, exsanguination, polyclonal antibodies, RIBI, TiterMax, MPL, SAF, and the specific immunogen & adjuvant_______________________________________________________ A search for alternatives was conducted on ___________________ (date) of Web of Science covering the years 20___ - 20___ (> last 10 years) using the search terms animal, rabbit, research, pain, antiserum, antibody production, alternatives, antigen, inflammation, adjuvant, immunogen, early endpoint, anesthesia, analgesia, exsanguination, polyclonal antibodies, RIBI, TiterMax, MPL, SAF, and the specific immunogen & adjuvant________________________________________________  Non-animal alternatives were considered, less sentient species were considered, and none were found suitable for antiserum production  Alternatives to painful procedures were considered, none were found suitable, and methods used in antiserum production will be continuously refined so as to reduce animal discomfort  Animal use for antiserum production does not unnecessarily duplicate previous research or existing studies Antiserum production using NZW rabbits by Comparative Medicine in accordance with IACUC Principle XVII is requested without exception, including all administrations, observations, phlebotomies, and treatments made and recorded by Comparative Medicine, and that the requesting investigator will provide the immunizing antigen to the Facility Manager, who will in turn coordinate and supervise the service 3. ANTIGEN PREPARATION. Name and describe the antigen(s) of interest (e.g., IL-1 receptor), and the preparation(s) (e.g., soluble, insoluble or particulate protein, or peptides conjugated to carrier proteins, or carbohydrates, etc.):  Antigen(s): Preparation(s): 4. ANIMALS. Indicate the total number of rabbits requested (i.e., 2-4 rabbits/antigen): 5. SPECIAL CONSIDERATIONS. Check only if applicable, that:  Complete Freund's Adjuvant (CFA) is required for this request  The searches for alternatives above includes the search terms CFA, anesthesia, exsanguination, polyclonal antibodies, adjuvant, pain, abscess, alternative adjuvants, RIBI, TiterMax, MPL, SAF, and early endpoint  The following scientific justification is provided for the use of Complete Freunds Adjuvant:  __________________________________________________________________________________________________ Requesting Faculty Members Signature Date     PAGE 1 CMDC #203.1 Effective 11/15 Page  PAGE 1 of  NUMPAGES 1  Cdhi    ȶȶ՜~sh]Sh[CJOJQJhZC5CJOJQJhwg5CJOJQJh[5CJOJQJh#?h1y5CJOJQJaJh[CJOJQJh@Q<jh@Q<U#hj5h$0J5CJOJQJ^J"jh$5CJOJQJU^Jh$5CJOJQJ^Jh1y5CJOJQJ^Jh!1h!15CJOJQJ^J h[CJh[h1y : ; FHkl^gd1y^gd:gd1y $7$8$H$a$gd1ygd1y   9 : ; V ^ i t v | ʹ|laVKaCh1yOJQJhZC5CJOJQJh1y5CJOJQJh[5CJOJQJh#?h[5CJ OJQJaJ hNOCJOJQJ^Jh1yCJOJQJh1yCJOJQJ^Jh4h[CJOJQJ^JhwgCJOJQJ^J h$h[CJOJQJ^JaJh1yh[5CJOJQJh[CJOJQJ&jh#?CJOJQJUmHnHuh#?CJOJQJ  & ' > E H O W \ a b d f l m n o p r s t y 0 ; _  % ( Ǽh$OJQJhhOJQJh>*OJQJhh>*OJQJhOJQJh:_OJQJh1yh1yOJQJh?mOJQJ"jh:OJQJUmHnHuhRh1yCJ OJQJaJ h1yOJQJh:OJQJ0( 6 7 @ D R S U V W X Y Z [ ` j k  # G p FGHklm夯zoh[5CJOJQJhZC5CJOJQJh#?h1yCJ OJQJaJ hdOJQJh1yOJQJh1yh1yOJQJ"jh:OJQJUmHnHuh$OJQJhh>*OJQJhOJQJh:_OJQJh:OJQJh1yh:OJQJh}lOJQJ* -yz02345')*,-/gdIT^gd-gd-   !$%+-.5wyzƾynynffVnNFNFh-OJQJh9"pOJQJh#?h[5CJ OJQJaJ h?;܄u䴳ϴԱ!1䴳ϴ󲹻䴳ϴ}䴳ϴ$䴳ϴ䴳ϴ󰪲<hYhY0JmHnHu hY0Jjh!10JUhhadVh%jh%UhIThITCJOJQJaJ./0234567BCDP`gd:&`#$zrchIThITCJOJQJaJhwgOJQJhwghwgCJOJQJaJhwgh9"pCJOJQJaJh9"p5OJQJh-5OJQJh$hYCJOJQJaJhYCJOJQJaJh$h$CJOJQJaJh$hZCCJOJQJaJh:h:5OJQJh@Q<hYOJQJh%$gd9"pgd-gdZCgd:gdIT.:p#?/ =!@"@#$% ^ 2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH 8`8 !1Normal_HmH sH tH <@< !1 Heading 1$@&OJQJDA`D Default Paragraph FontRiR 0 Table Normal4 l4a (k ( 0No List :B@: !1 Body Text CJOJQJBP@B !1 Body Text 25CJOJQJ4 @4 !1Footer !.)@!. !1 Page Number4@24 !1Header !:>@B: !1Titlea$5CJOJQJH@RH !1 Balloon TextCJOJQJ^JaJ6U`a6 !1 Hyperlink >*B*phBqB ,apple-converted-spacef@f : List Paragraphd^m$CJOJPJQJ^JaJB'`B ?mComment ReferenceCJaJ4@4 ?m Comment Text:: ?mComment Text CharLj@L ?mComment Subject5\mHsHtHFoF ?mComment Subject Char5\PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK]  !   !#"$ !$ 0 \^`c ( & / h XX>EGLWYc!!T %# @H 0(  $T(  \  # #" ? \  # #" ?  P     "?   V  # "? V  # "? V  # "? V  # "? V  # "? V  # "? V   #  "? V ! # !"?   V " # ""?   V # # #"?   P $  "?  B S  ?Fl 0  *tQ2tQPtQ<tQ[tQytQet e+t0*+t [0*wt!Qmt#Qmt"QY t$0*ot8u;9u;:u;;u;*urn:schemas-microsoft-com:office:smarttags PersonName PBPiq +,?QY 5 5 & ' ) * , - / 0 2 3 7 A Z Z [ \ e o s  5 ' ) * , - / 0 2 3 33h;V]]^iv|(62 & ' ' ) * * , - / 0 2 3 7 D D M O Z _ e o s h;V]]^iv|(62 & ' ' ) * * , - / 0 2 3 7 D D M O Z _ $9  ^i,hh^h`o(.^`OJQJo(hH^`OJQJ^Jo(hHop^p`OJQJo(hH@ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJQJo(hH^`OJQJo(hH^`OJQJ^Jo(hHoP^P`OJQJo(hH$9 ^i          L<8XR= oA+ JL ,4hj@~ITJ#V8T{D`"h"&-#:'%'(1*?@ABERoot Entry F KuG1Table3WordDocument00SummaryInformation(3DocumentSummaryInformation8;CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q